[1] 夏维波,章振林,林华,等.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.
[2] JOHNELL O, KANIS JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17:1726-1733.
[3] EASTELL R, PAWEL SZULC P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5: 908-923.
[4] MURACA M, CAPPARIELLO A. The role of extracellular vesicles (EVs) in the epigenetic regulation of bone metabolism and osteoporosis. Int J Mol Sci. 2020;21:8682.
[5] CIUFFI S. Circulating microRNAs as novel biomarkers for osteoporosis and fragility fracture risk: is there a use in assessment risk? Int J Mol Sci. 2020;21:6927.
[6] ZHU Z, ZHOU H, WANG Y, et al. Associations between bone turnover markers and bone mineral density in older adults. J Orthop Surg (Hong Kong). 2021;29(1):467-475.
[7] SAMOCHA-BONET D, JUSTO D, ROGOWSKI O, et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm. 2008;2008:834153.
[8] FAIN JA. NHANES. Diabetes Educ. 2017;43(2):151.
[9] AHLUWALIA N, DWYER J, TERRY A, et al. Update on NHANES Dietary Data: Focus on Collection, Release, Analytical Considerations, and Uses to Inform Public Policy. Adv Nutr. 2016;7(1):121-134.
[10] FULGONI K, FULGONI VL. Trends in Total, Added, and Natural Phosphorus Intake in Adult Americans, NHANES 1988-1994 to NHANES 2015-2016. Nutrients. 2021;13(7):2249.
[11] DARIMONT T, KARAVASILOGLOU N, HYSAJ O, et al. Body weight and self-perception are associated with depression: Results from the National Health and Nutrition Examination Survey (NHANES) 2005-2016. J Affect Disord. 2020;274:929-934.
[12] 丛玉隆,金大鸣,王鸿利,等.中国人群血小板各项参数的调查分析[J].中华检验医学杂志,2004,27(6):35-37.
[13] LINDEN MD, JACKSON DE. Platelets: Pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol. 2010;42(11):1762-1766.
[14] KHODADI E. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules. Cardiovasc Toxicol. 2020; 20(1):1-10.
[15] YIN H, SHI A, WU J. Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes. 2022;15:2003-2030.
[16] ELSON A, ANUJ A, BARNEA-ZOHAR M, et al. The origins and formation of bone-resorbing osteoclasts. Bone. 2022;164:116538.
[17] YE J, XIAO J, WANG J, et al. The Interaction Between Intracellular Energy Metabolism and Signaling Pathways During Osteogenesis. Front Mol Biosci. 2022;8:807487.
[18] CIOVACCO WA, CHENG YH, HOROWITZ MC, et al. Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation. J Cell Biochem. 2010;109(4):774-781.
[19] TAYLOR KA, MAHAUT-SMITH MP. Ion channels and ion homeostasis in the platelet and megakaryocyte. Platelets. 2021;32(7):853-854.
[20] RAWISH E, NORDING H, MÜNTE T, et al. Platelets as Mediators of Neuroinflammation and Thrombosis. Front Immunol. 2020;11: 548631.
[21] MIYAMOTO K. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med. 2011;208:2175-2181.
[22] WAGNER DD, BURGER PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23(12):2131-2137.
[23] WEYRICH AS, ZIMMERMAN GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25(9):489-495.
[24] INTINI G. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials. 2009;30(28):4956-4966.
[25] MAJIDINIA M, SADEGHPOUR A, YOUSEFI B. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233(4): 2937-2948.
[26] KHAN FA, PARAYARUTHOTTAM P, ROSHAN G, et al. Platelets and Their Pathways in Dentistry: Systematic Review. J Int Soc Prev Community Dent. 2017;7(Suppl 2):S55-S60.
[27] CAMARGO PM, LEKOVIC V, WEINLAENDER M, et al. Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. J Periodontal Res. 2002;37:300-306.
[28] LITVINOVA L, YUROVA K, SHUPLETSOVA V, et al. Gene Expression Regulation and Secretory Activity of Mesenchymal Stem Cells upon In Vitro Contact with Microarc Calcium Phosphate Coating. Int J Mol Sci. 2020;21(20):7682.
[29] PARSONS P, BUTCHER A, HESSELDEN K, et al. Platelet-rich concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2 messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: A mode of action to enhance bone repair. J Orthop Trauma. 2008;22:595-604.
[30] SUMIDA R, MAEDA T, KAWAHARA I, et al. Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts. Exp Ther Med. 2019;18(1):358-365.
[31] ZHANG N, WU YP, QIAN SJ, et al. Research progress in the mechanism of effect of PRP in bone deficiency healing. ScientificWorldJournal. 2013;2013:134582.
[32] SCHMIDMAIER G, HERRMANN S, GREEN J, et al. Quantitative assessment of growth factors in reaming aspirate, iliac crest, and platelet preparation. Bone. 2006;39(5):1156-1163.
[33] GRUBER R, KARRETH F, FISCHER MB, et al. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone. 2002;30(5):726-732.
[34] CARDOSO CL, CURRA C, CURI MM, et al. Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses. Braz Oral Res. 2019; 33:e050.
[35] YAO Z, GETTING SJ, LOCKE IC. Regulation of TNF-Induced Osteoclast Differentiation. Cells. 2021;11(1):132.
[36] WANG D, WENG Y, GUO S, et al. Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling. Int J Mol Med. 2018;41(2):729-738.
[37] LI XS, ZHANG JR, MENG SY, et al. Mean platelet volume is negatively associated with bone mineral density in postmenopausal women. J Bone Miner Metab. 2012;30(6):660-665.
[38] AKBAL A, GÖKMEN F, GENCER M, et al. Mean platelet volume and platelet distribution width can be related to bone mineralization. Osteoporos Int. 2014;25:2291-2295.
[39] PIRSL F, CURTIS LM, STEINBERG SM, et al. Characterization and risk factor analysis of osteoporosis in a large cohort of patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2016; 22(8):1517-1524.
[40] KIM J, KIM HS, LEE HS, et al. The relationship between platelet count and bone mineral density: results from two independent population-based studies. Arch Osteoporos. 2020;15(1):43.
[41] KRISTJANSDOTTIR HL, MELLSTRÖM D, JOHANSSON P, et al. High platelet count is associated with low bone mineral density: The MrOS Sweden cohort. Osteoporos Int. 2021;32(5):865-871.
[42] WATANABE Y, TSUCHIYA A, TERAI S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol. 2021;27(1):70-80.
[43] DENG P, YUAN Q, CHENG Y, et al. Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging. Cell Stem Cell. 2021;28(6):1057-1073.e7.
[44] KIM PG, NIROULA A, SHKOLNIK V, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021;218(12): e20211872.
[45] ZHAO X, ZHANG C, CUI X, et al. Interactions of Hematopoietic Stem Cells with Bone Marrow Niche. Methods Mol Biol. 2021;2346:21-34.
[46] YANG S, ZHANG F, MA J, et al. Intervertebral disc ageing and degeneration: The antiapoptotic effect of oestrogen. Ageing Res Rev. 2020;57:100978.
[47] HIKIJI H, ISHII S, SHINDOU H, et al. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy. J Clin Invest. 2004;114(1):85-93. |